• search
Antibody-Drug Conjugate (ADC) Services Antibody-Drug Conjugate (ADC) Services

Antibody-Drug Conjugate (ADC) Services

Integrated ADC discovery to development—spanning antibody engineering, linker-payload design, conjugation, and evaluation—to deliver high-quality, targeted cancer therapies.

We offer comprehensive and integrated ADC discovery and development services, from antibody engineering and linker-payload design to conjugation, analysis, and biological evaluation, enabling the creation of potent and targeted cancer therapies.

Our expertise spans novel linker and payload development, efficient conjugation chemistries, and robust analytical and biological characterization, ensuring the generation of high-quality ADCs tailored to your specific therapeutic needs.

Child Page Segments:

Additional Information:

  • Our bioconjugation capabilities extend beyond traditional ADCs to include antibody/protein oligo conjugates, metal-free DOTA conjugation, biotinylation, and FITC labeling.
  • We have a proven track record, with numerous projects delivered, development candidates nominated, and satisfied customers.
  • Over 20 years of proven expertise in designing and developing novel compounds for Oncology and other therapeutic areas, enabling deep scientific insight and innovation.
  • Dedicated CADD and AI/ML team with extensive experience in supporting ADC design and optimization, accelerating the path from concept to candidate.
  • 5 integrated ADC discovery programs.
  • 17 Projects delivered.
  • 2 Development candidates nominated.
  • 10+ Customers served.
 

Why Aurigene Antibody Drug Conjugate Services?

Site-specific conjugation technology

In-house linker library & Payload

Collaborative and solution driven

Analytical assessment to ensure safety and quality

Various commercial and customized linkers

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...

Read More
Systematic formulation design - shorten development cost & time

Systematic formulation design - shorten development cost & time

Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...

Read More

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives

2016

A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack